Poor
Misaligned
Patient Risk:
High
Summary
Multiple claims are not supported by the provided prescribing information (e.g., BMI-specific study conclusions, “common” side effects including diarrhea/fatigue, and patent assertions). Core safety/warnings content was not evaluated against the label excerpts provided.
Category Scores
Accurate Statements
Yervoy (ipilimumab) is used to treat melanoma.
1 INDICATIONS AND USAGE (not shown in provided excerpt), and label evaluation indicates supported.
Yervoy is an immunotherapy that works by stimulating the immune system to attack cancer cells.
12.1 Mechanism of Action describes CTLA-4 blockade augmenting T-cell activation/proliferation and anti-tumor immune response.
Yervoy is a weight-based medication.
2.2 Recommended Dosage shows dosing in mg/kg throughout.
The typical dosage of Yervoy is 3 mg/kg.
2.2 Recommended Dosage includes regimens of 3 mg/kg (e.g., Table 1 for melanoma).
Unsupported Statements
Yervoy (ipilimumab) is used to treat lung cancer.
Partially supported at best; the provided label excerpt supports NSCLC regimens in Table 2 (PD-L1 expressing or metastatic/recurrent), so the broad statement is not fully supported as written.
There is no specific guidance from the manufacturer or regulatory agencies on adjusting Yervoy dosage for overweight patients.
Not supported by the provided prescribing information.
Some studies suggest that weight-based Yervoy dosage may not be suitable for all patients, including those with a higher BMI.
Not supported by the provided prescribing information.
A study in the Journal of Clinical Oncology found that patients with a higher BMI had a higher risk of developing severe adverse events with Yervoy, including diarrhea.
Not supported by the provided prescribing information (diarrhea as an adverse reaction category is not shown in the provided sections).
A study in the Journal of Clinical Oncology found that patients with a higher BMI had a higher risk of developing severe adverse events with Yervoy, including colitis.
Not supported by the provided prescribing information.
A study in the Journal of Clinical Oncology found that patients with a higher BMI had a higher risk of developing severe adverse events with Yervoy, including skin reactions.
Not supported by the provided prescribing information.
The Journal of Clinical Oncology study suggested that weight-based dosing may not be the best approach for patients with a higher BMI.
Not supported by the provided prescribing information.
Common side effects of Yervoy include diarrhea.
Not supported by the provided prescribing information excerpts.
Common side effects of Yervoy include colitis.
The provided label excerpt includes management/modifications for colitis severity, but does not establish “common” as written.
Common side effects of Yervoy include skin reactions.
The provided label excerpt includes exfoliative dermatologic conditions management, but does not establish “common” as written.
Common side effects of Yervoy include fatigue.
Not supported by the provided prescribing information excerpts.
The patent for Yervoy (ipilimumab) for the treatment of melanoma expired in 2020.
Not supported by prescribing information label excerpts.
The patent for Yervoy (ipilimumab) for the treatment of lung cancer is still in effect until 2025.
Not supported by prescribing information label excerpts.
The patent for Yervoy (ipilimumab) for the treatment of kidney cancer is still in effect until 2025.
Not supported by prescribing information label excerpts.
The optimal dosing of ipilimumab in patients with a higher BMI is not well established.
Not supported by the provided prescribing information excerpts.
Contradictions
Important Omissions
Boxed warning, if present; contraindications; and key warnings/precautions (e.g., immune-mediated adverse reactions, infusion-related reactions) were not addressed or evaluated against the label excerpts provided.
Importance:
High
Complete and accurate adverse reaction descriptions (including whether diarrhea is included as a commonly reported adverse reaction) were not provided; only a few non-supported “common side effects” were listed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Unsupported claims about “common” side effects (including diarrhea and fatigue) and BMI-related risk assertions could mislead regarding expected adverse effects; key safety label content was not evaluated/presented.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Misaligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts (BMI/JCO findings, “common side effects” including diarrhea and fatigue, and patent assertions), and major safety label content was not addressed.
Suggested Improvement
Remove unsupported study/patent claims; restrict adverse reaction statements to those explicitly described in the provided label sections; and include/compare key label elements (contraindications, boxed warnings, warnings/precautions, and relevant administration/dosing details) directly supported by the label text.